ASSESSMENT OF FLEXIBLE NITINOL STENT PATENCY FOR MANAGEMENT OF FEMOROPOPLITEAL DISEASE

Korany, Ahmed Osman; El Askary, Naguib Abd Elkarem; Kassem, Ahmed; Fath Saad, Waleed Mabrouk

doi:10.21608/alexpo.2025.370590.2118

|
|
|
How to cite
RIS EndNote BibTeX APA MLA Harvard Vancouver
|
Share

	ASSESSMENT OF FLEXIBLE NITINOL STENT PATENCY FOR MANAGEMENT OF FEMOROPOPLITEAL DISEASE
Article 1, Volume 7, Issue 1, January 2025, Page 62-63
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2025.370590.2118
View on SCiNiTO
Authors
Ahmed Osman Korany¹; Naguib Abd Elkarem El Askary¹; Ahmed Kassem²; Waleed Mabrouk Fath Saad ²
¹Department of Surgery Faculty of Medicine University of Alexandria
²Department of Surgery, Faculty of Medicine, Alexandria University
Abstract
Introduction Peripheral artery disease (PAD) is a condition causing arterial narrowing, primarily affecting blood flow to the legs and feet. It is influenced by risk factors like diabetes and smoking, leading to pain, tissue loss, and gangrene. PAD affects 3% to 12% of the global population, with severe cases more common in women and individuals over 40. The femoro-popliteal artery is a key site for PAD, facing mechanical stresses like compression and torsion. Balloon angioplasty is the first-line treatment, but its limited durability often necessitates stenting for better vessel patency. Traditional stents, including laser-cut types, have drawbacks like fractures and inflammation. Advances in biomimetic materials have led to flexible nitinol stents (e.g., Supera stent), designed to withstand stress and improve outcomes. Lesions are classified using TASC II criteria based on type, length, and location. This study evaluates the effectiveness of flexible nitinol stents in femoropopliteal disease management. Aim: The aim of this study was to evaluate the flexible nitinol stent in the management of femoropopliteal disease.
Keywords
FLEXIBLE; NITINOL; STENT
Supplementary Files 2118 10 (85).pdf

Statistics Article View: 18